NR1I2 and prostate carcinoma: It is reported that fucoxanthin can be used as a PXR antagonist, not only promotes apoptosis of prostate cancer cells (PC-3, DU145 and LNCaP) through G0/G1 phases arrest, but also enhances the activation of caspase-3 in cisplatin-resistant HepG2 cells 114, 146.